The Form 4 filing, an SEC report of insider stock activity, was filed on October 29, 2026. It covers trades from October 27 through October 29 by Vaseem Mahboob, chief financial officer of Kestra Medical Technologies (KMTS).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-27 |
| Date of Latest Transaction | 2026-10-29 |
| Buy/Sell | sell |
| Transaction Count | 3 |
| Shares Transacted | 79,500 |
| Price | $30.30 |
| Total Transaction Value | $2,408,590.23 |
| Insider | |
| Ticker Symbol | KMTS |
| Company | KESTRA MEDICAL TECHNOLOGIES, LTD. |
| Insider Name | Mahboob Vaseem |
| Insider Title | Chief Financial Officer |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 60,609 |
| Position Size Change | 56.74% |
| Filing | |
| Filing Date | 2026-10-29 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales under transaction code S. The transaction information also suggests a link to an exercise or conversion. That process can turn a right to buy shares, or another holding, into stock.
What was the average price of the transaction?
The average sale price was $30.30 per share across the three transactions, rounded to the nearest cent.
How did this transaction affect the insider's holdings?
Vaseem Mahboob sold 79,500 shares and reported owning 60,609 shares afterward. The shares sold represented 56.74% of the shares he owned before the sales.
What's the total transaction value?
The three sales had a total value of $2,408,590.23, rounded to cents. That amount covers all three transactions.
Are there any special circumstances around this transaction?
A Rule 10b5-1 reference points to trading instructions set in advance. Footnote text is unavailable, so the plan's terms and which sales it covers cannot be confirmed.
Matching share counts also suggest a link to an acquisition under code M, used for an exercise or conversion. The related acquisition entries are unavailable. The match alone does not confirm that the shares received were the ones sold, or that both steps happened on the same day.
For research purposes only; not investment advice.